Search | TVST | ARVO Journals

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

36-month outcomes of VEGF inhibitors for treatment-naïve Central Retinal Vein Occlusion: Data from the Fight Retinal Blindness! registry.

Adrian Hunt; Vuong Nguyen; Sanjeeb Bhandari; Jennifer J Arnold; Ian McAllister; Hemal Mehta; Alessandro Invernizzi; David Squirrell; Theodorus Ponsioen; Pierre-Henry GABRIELLE; Louise O’ Toole; Javier Zarranz-Ventura; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2674. doi:

ARVO Annual Meeting Abstract June 2022

Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical Practice: the Fight Retinal Blindness! Registry

Pierre-Henry GABRIELLE; Vuong Nguyen; Jennifer J Arnold; David Squirrell; Louis Arnould; Jorge Sanchez-Monroy; Francesco Viola; Louise O’ Toole; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1344 – F0178. doi:

Articles November 2021

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

PDF

Pierre-Henry Gabrielle; Vuong Nguyen; Jennifer J. Arnold; Sanjeeb Bhandari; Francesco Viola; Odette A. M. Tigchelaar-Besling; Gonzaga Garay-Aramburu; Louise O'Toole; Chui Ming Gemmy Cheung; Daniel Barthelmes; Catherine Creuzot-Garcher; Mark Gillies
TAGS: atrophoderma maculatum, exudative age-related macular degeneration, eye, fibrosis
Trans. Vis. Sci. Tech.. 2021; 10(13):5. doi: https://doi.org/10.1167/tvst.10.13.5

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen

Christoph Grechenig; Gregor Sebastian Reiter; Sophie Riedl; Jennifer Arnold; Robyn H Guymer; Bianca S Gerendas; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):104. doi:

ARVO Annual Meeting Abstract June 2020

Automated quantification of retinal fluid and its impact on treatment outcomes in the FLUID study

Christoph Grechenig; Jennifer Joan Arnold; Hrvoje Bogunovic; Robyn H Guymer; Amir Sadeghipour; Bianca S S. Gerendas; Gregor Sebastian Reiter; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3507. doi:

ARVO Annual Meeting Abstract July 2019

Optimizing treat and extend regimens using artifical intelligence based on OCT imaging in the FLUID study

Jennifer Joan Arnold; Hrvoje Bogunović; Robyn H Guymer; Sebastian M Waldstein; Caroline Markey; Amir Sadeghipour; Bianca S Gerendas; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5190. doi:

ARVO Annual Meeting Abstract July 2019

Changes in real world treatment patterns for diabetic macular edema and five year treatment outcomes: data from the Fight Retinal Blindness! Project

SANJEEB BHANDARI; Anne Catherine Biechl; Jennifer Joan Arnold; Stephanie Young; Samanta Fraser-Bell; Hemal Mehta; Mark C Gillies; Daniel Barthelmes; Vuong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2602. doi:

ARVO Annual Meeting Abstract July 2019

Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration

Mark C Gillies; SANJEEB BHANDARI; Benjamin Wolff; Jennifer Joan Arnold; Rohan W Essex; Stephanie Young; David M Squirrell; Daniel Barthelmes; Vuong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):111. doi:

ARVO Annual Meeting Abstract July 2019

Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months

Vuong Nguyen; Anagha Vaze; Samanta Fraser-Bell; Jennifer Joan Arnold; Rohan W Essex; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):139. doi:

ARVO Annual Meeting Abstract July 2018

Tissue artefacts in post mortem human eyes.

Svetlana Cherepanoff; Lay Khoon Too; Victoria Pye; Murray Killingsworth; Alex Allende; Alessandro Invernizzi; Alex Hunyor; James Wong; Jennifer Arnold; Rohan Merani; Michael Rodriguez; Michele C Madigan; Geoff Hall

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):330. doi:

ARVO Annual Meeting Abstract July 2018

Comparison of Ranibizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration treated following a ‘Treat and Extend’ protocol: efficacy variables from the pre-specified 12-month interim analysis of the RIVAL study

Mark C Gillies; Alex Hunyor; Jennifer Arnold; Francois Pecheur; Kathryn Underhill; Robyn H Guymer; Ian McAllister

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):840. doi:

ARVO Annual Meeting Abstract July 2018

Tolerating Subretinal Fluid in the Treatment of Neovascular Age-Related Macular Degeneration With Ranibizumab Using a Treat and Extend Regimen

Jennifer Arnold; Caroline Markey; Ian McAllister; Mark C Gillies; Alex Hunyor; Robyn H Guymer

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1461. doi:

ARVO Annual Meeting Abstract June 2017

RANIBIZUMAB VERSUS AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: DATA FROM A PROSPECTIVE OBSERVATIONAL STUDY

Daniel Barthelmes; Anagha Vaze; Vuong Nguyen; Vincent Daien; Jennifer J Arnold; Stephanie H Young; Nigel Morlet; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):888. doi:

ARVO Annual Meeting Abstract June 2017

Twelve-month outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: an observational study.

Mark C Gillies; Vincent Daien; Vuong Nguyen; Jennifer J Arnold; Nigel Morlet; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):896. doi:

ARVO Annual Meeting Abstract September 2016

Risk of Age-related Macular Degeneration 5 Years after Cataract Surgery: Findings from a cataract surgical cohort

Jie Jin Wang; Calvin Sze-un Fong; George Burlutsky; Sudha Cugati; Ava Grace Tan; Elena Rochtchina; Jennifer Arnold; Wayne Smith; Paul Mitchell

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):15. doi:

ARVO Annual Meeting Abstract September 2016

Twelve-Month Outcomes of “Treat and Extend” aflibercept Therapy for Neovascular Age-Related Macular Degeneration

Daniel Barthelmes; Vuong Nguyen; Jennifer Arnold; Ian McAllister; Robyn Guymer; Rohan Essex; Stephanie Young; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):521. doi:

ARVO Annual Meeting Abstract September 2016

Twelve months outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: observational study data

Mark C Gillies; Richard Walton; Jennifer Arnold; Rohan Essex; Nigel Morlet; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):523. doi:

ARVO Annual Meeting Abstract June 2015

Effects of Switching from Ranibizumab to Aflibercept on Visual Outcome, Lesion Activity and Treatment Intensity in Eyes with Neovascular Age-Related Macular Degeneration

Daniel Barthelmes; Anna E Campain; Jennifer J Arnold; Ian McAllister; Judy M Simpson; Alex P Hunyor; Robyn H Guymer; Rohan W Essex; Nigel Morlet; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4589. doi:

ARVO Annual Meeting Abstract April 2014

Outcomes of Persistently Active Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors: Observational Study data

Daniel Barthelmes; Richard Walton; Judy M Simpson; Jennifer Arnold; Ian McAllister; Robyn H Guymer; Alex Paul Hunyor; Rohan W Essex; Nigel Morlet; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1308. doi:

Clinical and Epidemiologic Research August 2013

Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-Naïve Eyes

PDF

Mark C. Gillies; Richard Walton; Judy M. Simpson; Jennifer J. Arnold; Robyn H. Guymer; Ian L. McAllister; Alex P. Hunyor; Rohan W. Essex; Nigel Morlet; Daniel Barthelmes
TAGS: alcohol use disorders identification test, exudative age-related macular degeneration, eye, financial audit, injections, follow-up
Invest. Ophthalmol. Vis. Sci.. 2013; 54(8):5754-5760. doi: https://doi.org/10.1167/iovs.13-11993

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

36-month outcomes of VEGF inhibitors for treatment-naïve Central Retinal Vein Occlusion: Data from the Fight Retinal Blindness! registry.

Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical Practice: the Fight Retinal Blindness! Registry

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen

Automated quantification of retinal fluid and its impact on treatment outcomes in the FLUID study

Optimizing treat and extend regimens using artifical intelligence based on OCT imaging in the FLUID study

Changes in real world treatment patterns for diabetic macular edema and five year treatment outcomes: data from the Fight Retinal Blindness! Project

Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration

Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months

Tissue artefacts in post mortem human eyes.

Comparison of Ranibizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration treated following a ‘Treat and Extend’ protocol: efficacy variables from the pre-specified 12-month interim analysis of the RIVAL study

Tolerating Subretinal Fluid in the Treatment of Neovascular Age-Related Macular Degeneration With Ranibizumab Using a Treat and Extend Regimen

RANIBIZUMAB VERSUS AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: DATA FROM A PROSPECTIVE OBSERVATIONAL STUDY

Twelve-month outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: an observational study.

Risk of Age-related Macular Degeneration 5 Years after Cataract Surgery: Findings from a cataract surgical cohort

Twelve-Month Outcomes of “Treat and Extend” aflibercept Therapy for Neovascular Age-Related Macular Degeneration

Twelve months outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: observational study data

Effects of Switching from Ranibizumab to Aflibercept on Visual Outcome, Lesion Activity and Treatment Intensity in Eyes with Neovascular Age-Related Macular Degeneration

Outcomes of Persistently Active Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors: Observational Study data

Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-Naïve Eyes

To View More...

You must be signed into an individual account to use this feature.